Pancreatic ductal adenocarcinoma (PDAC) is a painful, deadly, and incurable disease for which effective treatments remain to be discovered and tested. The OVERALL OBJECTIVES of this study are to define mechanisms underlying the regulation of PDAC cell growth, by focusing on further characterizing a novel pathway for which individual components can be targeted pharmacologically. Previous studies along with our preliminary data indicate that mitotic aberrations and PDAC cell growth, two highly interrelated processes, rely on signaling from Aurora A (AurkA) to the HP1?-G9a pathway. Mutations or aberrant expression of either AurkA or the HP1? -G9a complex are implicated in the development of neoplasms of different origins, including PDAC. We will test the CENTRAL HYPOTHESIS that a novel AurkA-HP1?-G9a pathway regulates mitotic progression and PDAC cell growth in a manner amenable to pharmacological inhibition using combination therapy. Congruently, our SPECIFIC AIMS are: 1. To characterize the function of the HP1?-G9a complex as a downstream mediator of the effects of AurkA on mitotic progression in PDAC cells;2. To characterize cellular and molecular mechanisms that contribute to the inhibitory effects of the AurkA-HP1?-G9a pathway on PDAC growth;and 3. To characterize the effects of combined targeting of the AurkA-HP1?-G9a pathway on PDAC progression in orthotopic xenografts and genetically engineered mice models. Thus, our research will span from the level of molecules to cell populations to the whole organism. These studies are feasible for our laboratory, which has developed the appropriate conceptual framework, reagents, trained personnel and established collaborations to execute the proposed research. The design of this proposal is innovative as it seeks to maximize the yield of new mechanistic knowledge and pharmacological interventions, which impact on PDAC tumor growth. Since PDAC is a dismal disease, the discovery and proposed study of this novel AurkA-HP1?-G9a pathway bears significant biomedical relevance.

Public Health Relevance

These investigations represent a defined strategy to discover novel therapeutic approaches for pancreatic ductal adenocarcinoma, a painful and deadly disease that ranks 4th in USA cancer deaths, for which no effective treatment currently exists. We propose to investigate a pathway that regulates pancreatic cancer cell division and growth in a manner that can be exploited by combined therapies for the ultimate goal of treating this dismal disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Hildesheim, Jeffrey
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Lomberk, Gwen; Blum, Yuna; Nicolle, Rémy et al. (2018) Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun 9:1978
Seo, Seungmae; Mathison, Angela; Grzenda, Adrienne et al. (2018) Mechanisms Underlying the Regulation of HP1? by the NGF-PKA Signaling Pathway. Sci Rep 8:15077
Mathison, Angela; Salmonson, Ann; Missfeldt, Mckenna et al. (2017) Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe. Mol Cancer Res 15:984-997
Bian, Benjamin; Bigonnet, Martin; Gayet, Odile et al. (2017) Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med 9:482-497
Blackburn, Patrick R; Williams, Monique; Cousin, Margot A et al. (2017) A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation. Mol Genet Genomic Med 5:141-146
Blackburn, Patrick R; Tischer, Alexander; Zimmermann, Michael T et al. (2017) A Novel Kleefstra Syndrome-associated Variant That Affects the Conserved TPLX Motif within the Ankyrin Repeat of EHMT1 Leads to Abnormal Protein Folding. J Biol Chem 292:3866-3876
Lomberk, Gwen A; Iovanna, Juan; Urrutia, Raul (2016) The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics 8:831-42
Velez, Gabriel; Lin, Marisa; Christensen, Trace et al. (2016) Evidence supporting a critical contribution of intrinsically disordered regions to the biochemical behavior of full-length human HP1?. J Mol Model 22:12
Grasso, Daniel; Bintz, Jennifer; Lomberk, Gwen et al. (2015) Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation. Sci Rep 5:17549
Mathison, Angela; Escande, Carlos; Calvo, Ezequiel et al. (2015) Phenotypic Characterization of Mice Carrying Homozygous Deletion of KLF11, a Gene in Which Mutations Cause Human Neonatal and MODY VII Diabetes. Endocrinology 156:3581-95

Showing the most recent 10 out of 22 publications